Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma
NCT07707973
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Glioma, Malignant
Interventions
DRUG:
nimotuzumab
DRUG:
Temozolomide
RADIATION:
Radiotherapy
Sponsor
Tianjin First Central Hospital